Jason Chiang
YOU?
Author Swipe
View article: A Systematic Study of Molecular Diagnosis, Treatment and Prognosis in Infant-Type Hemispheric Glioma): An Individual Patient Data Meta-analysis of 164 patients
A Systematic Study of Molecular Diagnosis, Treatment and Prognosis in Infant-Type Hemispheric Glioma): An Individual Patient Data Meta-analysis of 164 patients Open
Background Due to the novelty and rarity of infant-type hemispheric glioma (IHG), optimal treatment and factors determining clinical outcomes are yet to be established. Methods We curated a series of 164 patients with IHG; 155 identified b…
View article: PTHP-03. Pediatric H3 G34-Mutant Diffuse Hemispheric Glioma: Unique biology and clinical behavior
PTHP-03. Pediatric H3 G34-Mutant Diffuse Hemispheric Glioma: Unique biology and clinical behavior Open
BACKGROUND H3 G34-mutant diffuse hemispheric glioma (DHG) is a newly recognized tumor type in WHO CNS5. Previous studies have demonstrated inferior outcomes in pediatric patients, but the underlying mechanisms remain unknown. Additionally,…
View article: NCMP-26. Tumor inflammation-associated neurotoxicities for patients treated with intracranial B7-H3-CAR T cells on a phase I clinical trial
NCMP-26. Tumor inflammation-associated neurotoxicities for patients treated with intracranial B7-H3-CAR T cells on a phase I clinical trial Open
CAR T-cell therapy is a promising approach for patients with high-risk CNS tumors. Neurological adverse events (AEs) are currently described using multiple methods, leading to discrepant reporting. The tumor inflammation-associated neuroto…
View article: CTP-08. Efficacy and tolerability of mirdametinib (PD-0325901) in children, adolescents, and young adults with recurrent/progressive low-grade glioma: update from the SJ901 (NCT04923126) phase 1/2 clinical trial
CTP-08. Efficacy and tolerability of mirdametinib (PD-0325901) in children, adolescents, and young adults with recurrent/progressive low-grade glioma: update from the SJ901 (NCT04923126) phase 1/2 clinical trial Open
BACKGROUND SJ901 trial was designed to determine the recommended Phase 2 dose (RP2D), safety, and efficacy of mirdametinib, an oral, selective MEK1/2 inhibitor (MEKi) with high blood-brain-barrier penetration, in patients with pediatric lo…
View article: Figure S6 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S6 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S6 shows B7-H3.CAR T-cell expansion vs EPN cell target antigen density.
View article: Figure S17 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S17 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S17 shows effective control of PFA EPN xenografts by B7-H3.CAR T-cells in vivo.
View article: Figure S22 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S22 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S22 shows IHC evaluation of B7-H3 expression and CD3+ cell infiltration inside syngeneic ZFTA-RELA EPN tumors.
View article: Figure S15 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S15 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S15 shows increased inhibitory marker expression on B7-H3.CAR T-cells compared to HER2.CAR T-cells following repeated stimulation with 1425 cell line.
View article: Figure S1 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S1 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S1 shows representative B7-H3 staining intensity scale.
View article: Figure S5 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S5 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S5 shows phenotypic characteristics of human B7-H3.CAR T-cells.
View article: Figure S21 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S21 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S21 shows IHC evaluation and quantification of immune cell infiltration inside syngeneic ZFTA-RELA EPN tumors.
View article: Figure S3 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S3 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S3 shows regulation of B7-H3 transcriptional activity by ZFTA-RELA oncogene.
View article: Figure S11 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S11 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S11 shows phenotypic characteristics of human HER2.CAR T-cells.
View article: Figure S7 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S7 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S7 shows inverse correlation between B7-H3.CAR T-cell expansion and B7-H3 target antigen density.
View article: Figure S13 legend1 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S13 legend1 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S13 legend
View article: Figure S19 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S19 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S19 shows successful infiltration of HER2.CAR T-cells inside 1425 EPN xenograft tumors.
View article: Figure S16 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S16 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S16 shows high potency but limited durability of B7-H3.CAR T-cells against ZFTA-RELA EPN xenograft tumors in vivo.
View article: Figure S9 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S9 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S9 shows Type 2 polarization of B7-H3.CAR T-cells over repetitive stimulation with EPN cells.
View article: Figure S10 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S10 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S10 shows increased CXCL10 secretion following repetitive stimulation compared to baseline secretion of B7-H3.CAR T-cells and EPN cells.
View article: Figure S8 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S8 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S8 shows inverse correlation between B7-H3 antigen upregulation on B7-H3.CAR T-cells post co-culture and B7-H3 density on EPN cells.
View article: Figure S18 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S18 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S18 shows tumor volume-dependent antitumor efficacy of HER2.CAR T-cells.
View article: Figure S2 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S2 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S2 shows the regulation of B7-H3 transcriptional activity by ZFTA-RELA oncogene.
View article: Data from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Data from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Purpose:Targeted treatments are desperately needed for ependymomas. Chimeric antigen receptor (CAR) T cells have immense potential to transform patient outcomes. However, CAR T-cell therapy for ependymomas has been largely understudied. In…
View article: Figure S20 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S20 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S20 shows in vitro efficacy of murine B7-H3.CAR T-cells against murine ZFTA-RELA EPN cell line.
View article: Figure S13 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S13 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S13 shows sustained or increased cytokine secretion of HER2.CAR T-cells following repetitive stimulation with EPN cells.
View article: Figure S4 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S4 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S4 shows antigen profiling of HER2 in ZFTA-fusion driven EPN cell lines.
View article: Figure S12 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S12 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S12 shows improved expansion and persistence of HER2.CAR T-cells over B7-H3.CAR T-cells against EPN cells.
View article: Table S1 and S2 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Table S1 and S2 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Supplementary Tables S1 and S2
View article: Figure S14 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
Figure S14 from B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response Open
Figure S14 shows comparison of phenotypic characteristics between B7-H3.CAR and HER2.CAR T-cells during repeated stimulation with 1425 cell line.
View article: Diffuse leptomeningeal glioneuronal tumor (DLGNT): a comprehensive clinical and molecular analysis
Diffuse leptomeningeal glioneuronal tumor (DLGNT): a comprehensive clinical and molecular analysis Open
Diffuse leptomeningeal glioneuronal tumors (DLGNTs) are rare, and optimal treatment remains undefined. We aim to comprehensively characterize their clinical and molecular features, offering granular insights into presentations and therapie…